BofA Securities Downgrades PTC Therapeutics (PTCT) to Neutral
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Price: $25.49 +1.11%
Rating Summary:
8 Buy, 9 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
8 Buy, 9 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad downgraded PTC Therapeutics (NASDAQ: PTCT) from Buy to Neutral.
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $62.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PTC Therapeutics (PTCT) Tops Q1 EPS by 9c, provides guidance
- Stifel Downgrades HashiCorp Inc (HCP) to Hold
- JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
